Colonic Diseases, Functional: Clinical Trials

137 trials for Colonic Diseases, Functional, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

92 completed, 15 unknown, 13 terminated, 12 recruiting. 137 Phase 2, 21 Phase 3, 10 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 2137Completed 92, Unknown 15, Terminated 13, Recruiting 12, Active not recruiting 2, Not yet recruiting 1, Suspended 1, Withdrawn 1
Phase 321Completed 9, Unknown 8, Recruiting 2, Active not recruiting 1, Terminated 1
Phase 110Completed 9, Recruiting 1

Follow Colonic Diseases, Functional: new trials by email Literature Review of Colonic Diseases, Functional trials Research Report on Colonic Diseases, Functional

Trials (filtered) newest first · largest first

All 137 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Herbal Supplement (Biocidin REMOVE) for Bacterial Overgrowth in Irritable Bowel Syndrome
Biocidin REMOVE, Placebo - Irritable Bowel Syndrome (IBS), Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
Phase 2RecruitingJohns Hopkins University402026-10-262026-11-16
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
LY3537031, Placebo - Irritable Bowel Syndrome, Diarrhea
Phase 2RecruitingEli Lilly and Company5312026-05-062026-11-04
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
LY3537031, Placebo - Irritable Bowel Syndrome, Constipation
Phase 2RecruitingEli Lilly and Company3422026-04-292026-11-05
A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)
Placebo, Camlipixant - Irritable Bowel Syndrome
Phase 2RecruitingGlaxoSmithKline4202026-04-082026-09-22
Safety and Efficacy of Lyophilized Faecal Microbiota Transplantation Via Capsules in Treatment of Irritable Bowel Syndrome
FMT capsule, Placebo - Irritable Bowel Syndrome (IBS)
Phase 1 / Phase 2RecruitingUniversity of Rijeka702026-03-152026-03-18
Efficacy of Rifaximin With NAC in IBS-D
rifaximin 66mg + N-acetylcysteine 560mg three times daily, RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily, Placebo - IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant)
Phase 2RecruitingMark Pimentel, MD2252026-02-042026-04-20
A Flexible Clinical Trial to Test if Freeze-dried Fecal Microbiota Therapy Helps Treat Diarrhea-predominant Irritable Bowel Syndrome or Prevent Recurring C. Difficile Infections.
ORAL-LYO-FMT, Placebo - Irritable Bowel Syndrome, Diarrhea-Predominant (IBS-D), Recurrent Clostridioides Difficile Infection (rCDI)
Phase 2Not yet recruitingPharmaPlanter Technologies Inc632025-09-012025-04-29
Effectiveness of a Dietary Supplement in Irritable Bowel Syndrome
treatment with DIELEN® Protect, treatment with placebo of DIELEN® Protect - Irritable Bowel Syndrome
Phase 2RecruitingUniversity Hospital, Rouen1002025-04-222026-02-23
Psyllium in Pediatric IBS
Psyllium (0.7 g/year of age per day), Psyllium (0.5 g/year of age per day), Placebo - Irritable Bowel Syndrome
Phase 2RecruitingDr Bruno Chumpitazi, M.D.1102025-02-202026-05-26
Effects of Standardized Boswellia Carterii Extract on Irritable Bowel Syndrome Patients
Boswellia carterii Extract, Educationntal program for IBS patie - Irritable Bowel Syndrome
Phase 2 / Phase 3CompletedMansoura University602025-01-012026-05-08
Comparison of Rimegepant and Placebo for Pain in IBS
Rimegepant 75 MG [Nurtec] - Irritable Bowel Syndrome
Phase 2CompletedMayo Clinic392024-06-062026-10-15
Fecal Microbiota Transplantation for IBS
Donor Fecal Microbiota Transplantation, Autologous Fecal Microbiota Transplantation - Irritable Bowel Syndrome, Diarrhea
Phase 2RecruitingMadhusudan (Madhu) Grover, MBBS432024-04-152026-05-08
Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)
TRYP-0082, Psychotherapy - Irritable Bowel Syndrome
Phase 2Active not recruitingTRYP Therapeutics142024-01-172026-02-05
Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).
CIN-103, Placebo - Irritable Bowel Syndrome With Diarrhea
Phase 2TerminatedCinPhloro Pharma, LLC4212023-12-282025-12-15
Efficacy of a Probiotic Blend to Reduce Gastrointestinal Symptoms in Patients With Irritable Bowel Syndrome
Probiotic blend, PLACEBO - Irritable Bowel Syndrome
Phase 2UnknownUniversidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude1142023-03-152023-04-19
The Use of Directed Probiotics in ME/CFS: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Floradapt Intensive GI, Placebo - ME/CFS, IBS - Irritable Bowel Syndrome
Phase 2RecruitingNova Southeastern University1002022-12-202025-03-04
Home Transcutaneous Electrical Acustimulation (TEA)
TEA, Lexapro - Irritable Bowel Syndrome With Constipation
Phase 2 / Phase 3RecruitingUniversity of Michigan1602022-11-022026-09-17
Neurocognitive Effects of FMT in MDD Patients With and Without IBS
Fecal Microbiota Transplantation - Major Depressive Disorder, Irritable Bowel Syndrome
Phase 2 / Phase 3Active not recruitingValerie Taylor1332022-04-062026-03-19
Exploratory Study on Dosage of Qizhi Weitong Granules in the Treatment of Irritable Bowel Syndrome (IBS)
Qizhi weitong granules(High), Qizhi weitong granules(Low), Placebo - Irritable Bowel Syndrome
Phase 2UnknownChina Resources Sanjiu Medical & Pharmaceutical Co., Ltd.1202021-12-012021-11-09
The Effects of Prucalopride in Patients With Constipation Predominant Irritable Bowel Syndrome
Prucalopride 2mg - Irritable Bowel Syndrome
Phase 2 / Phase 3UnknownBangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh1602021-03-102021-10-22

Showing 20 of 137. Sign in to see all of them.

Narrower conditions

Irritable Bowel Syndrome (136)  ·  Diarrhea (20)  ·  Abdominal Pain (14)  ·  Constipation (14)  ·  Gastrointestinal Diseases (6)  ·  Pain (5)  ·  Colonic Diseases (4)  ·  Digestive System Diseases (4)  ·  Intestinal Diseases (4)  ·  Ichthyosis Bullosa of Siemens (3)  ·  Depression (2)  ·  Fatigue Syndrome, Chronic (2)  ·  Fibromyalgia (2)  ·  Inflammation (2)

Broader conditions

Colonic Diseases (133)  ·  Digestive System Diseases (133)  ·  Intestinal Diseases (133)  ·  Gastrointestinal Diseases (131)  ·  Pathological Conditions, Signs and Symptoms (43)  ·  Signs and Symptoms (38)  ·  Signs and Symptoms, Digestive (34)  ·  Neurologic Manifestations (21)  ·  Pain (14)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6)  ·  Genetic Diseases, Inborn (6)  ·  Nervous System Diseases (6)  ·  Pathologic Processes (6)  ·  Skin and Connective Tissue Diseases (5)

Interventions

Fecal Microbiota Transplantation (8)  ·  Rifaximin (6)  ·  Probiotics (5)  ·  Sugars (4)  ·  GW 876008 (3)  ·  Mesalamine (3)  ·  linaclotide (3)  ·  12,13-dihydro-N-methyl-6,11,13-trioxo-5H-benzo(4,5)cyclohepta(1,2-b)naphthalen-5,12-imine (2)  ·  Acupuncture Therapy (2)  ·  DDP733 (2)  ·  Dronabinol (2)  ·  Lacteol (2)  ·  Medicine, Chinese Traditional (2)  ·  Nortriptyline (2)  ·  ONO-2952 (2)

Sponsors

GlaxoSmithKline (8)  ·  Mayo Clinic (7)  ·  Bausch Health Americas, Inc. (5)  ·  Astellas Pharma Inc (3)  ·  Dynogen Pharmaceuticals (3)  ·  Ironwood Pharmaceuticals, Inc. (3)  ·  Cedars-Sinai Medical Center (2)  ·  Chinese University of Hong Kong (2)  ·  Danisco (2)  ·  Eli Lilly and Company (2)  ·  Lexicon Pharmaceuticals (2)  ·  Maastricht University Medical Center (2)  ·  Menarini Group (2)  ·  National Center for Complementary and Integrative Health (NCCIH) (2)  ·  Ono Pharma USA Inc (2)

Countries

United States (73)  ·  Canada (16)  ·  United Kingdom (9)  ·  China (8)  ·  France (7)  ·  Germany (7)  ·  Netherlands (6)  ·  Spain (6)  ·  Sweden (6)  ·  Poland (5)  ·  Belgium (4)  ·  Japan (4)  ·  Australia (3)  ·  Bulgaria (3)  ·  Denmark (3)

Top investigators

Michael Camilleri, MD (5)  ·  Anna Lyra, PhD (2)  ·  Arthur Ouwehand, PhD (2)  ·  Dugald Seely, ND (2)  ·  Jan Tack, Professor (2)  ·  Lea Veijola, MD (2)  ·  Sampo Lahtinen, PhD (2)  ·  Ted Kaptchuk, OMD (2)  ·  A Masclee, Prof, PhD, MD (1)

Results publications

PMID 9146781, PMID 11239312, PMID 11491192, PMID 11914441, PMID 17013448, PMID 17043337, PMID 18390493, PMID 19879973, PMID 20594245, PMID 20801122, PMID 21803011, PMID 21883322, PMID 22288893, PMID 22347818, PMID 22517769, PMID 23554827, PMID 23583433, PMID 23618477, PMID 24018052, PMID 24697851, PMID 24813429, PMID 24815298, PMID 24891990, PMID 25987795, PMID 27080737, PMID 27196574, PMID 27910150, PMID 28164346, PMID 28167156, PMID 28205278, PMID 28252569, PMID 28483500, PMID 28720615, PMID 28932269, PMID 29100842, PMID 29980607, PMID 30108163, PMID 30284674, PMID 30525951, PMID 31326345, PMID 31499231, PMID 31594647, PMID 31800542, PMID 32536023, PMID 32620184, PMID 32991818, PMID 34774080, PMID 34854473, PMID 36269028, PMID 36324245

NIH funding

UL1RR024150 (3), 2025 (2), R01DK079866 (2), U19AT003266 (2), 2008 (1), 2014 (1), 2016 (1), 2017 (1), 5UH3NS115108-04 (1), R01DK054681 (1), R01HD096331 (1), R01NR004142 (1), R01NR005337 (1), R01NR010730 (1)